Abstract:Objective The aim of this study is to develop multistage prediction models for pre-eclampsia (PE) covering almost the entire pregnancy period based on routine antenatal measurements and to propose a risk screening strategy. Methods This was a retrospective cohort study that included 20582 singleton pregnant women with the last menstruation between January 1, 2013 and December 31, 2019. Of the 20582 women, 717 (3.48%) developed pre-eclampsia, including 46 (0.22%) with early-onset pre-eclampsia and 119 (0.58%) preterm pre-eclampsia. We randomly divided the dataset into the training set ( N = 15665), the testing set ( N = 3917), and the validation set ( N = 1000). Least Absolute Shrinkage And Selection Operator (LASSO) was used to do variable selection from demographic characteristics, blood pressure, blood routine examination and biochemical tests. Logistic regression was used to develop prediction models at eight periods: 5–10 weeks, 11–13 weeks, 14–18 weeks, 19–23 weeks, 24–27 weeks, 28–31 weeks, 32–35 weeks, and 36–39 weeks of gestation. We calculated the AUROC (Area Under the Receiver Operating Characteristic Curve) on the test set and validated the screening strategy on the validation set. Results We found that uric acid tested from 5–10 weeks of gestation, platelets tested at 18–23 and 24–31 weeks of gestation, and alkaline phosphatase tested at 28–31, 32–35 and 36–39 weeks of gestation can further improve the prediction performance of models. The AUROC of the optimal prediction models on the test set gradually increased from 0.71 at 5–10 weeks to 0.80 at 24–27 weeks, and then gradually increased to 0.95 at 36–39 weeks of gestation. At sensitivity level of 0.98, our screening strategy can identify about 94.8% of women who will develop pre-eclampsia and reduce about 40% of the healthy women to be screened by 28–31 weeks of pregnancy. Conclusion We developed multistage prediction models and a risk screening strategy, biomarkers of which were part of routine test items and did not need extra costs. The prediction window has been advanced to 5–10 weeks, which has allowed time for aspirin intervention and other means for PE high-risk groups.

OP15.03: Maternal cardiovascular hemodynamics for the prediction of pre‐eclampsia at 12–16 weeks

Umbilical and middle cerebral arteries Doppler velocimetry in early and late onset pre-eclampsia

OP15.04: Validation of the first trimester machine learning model for predicting pre‐eclampsia in Asian populations

EP17.24: Maternal ophthalmic artery Doppler in normal pregnancy and pre‐eclampsia and its association with pregnancy outcome

OP13.05: Assessment of the angiogenic ratio versus glycosylated fibronectin in predicting adverse maternal outcome in women with suspected pre‐eclampsia

EP08.21: Prediction of adverse intrapartum outcomes at 35–37 weeks

P182 AORTIC VASCULAR BIOMARKERS FOR THE EARLY DETECTION OF PLACENTAL SYNDROMES DURING PREGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS

EP17.54: Assessment of the angiogenic ratio versus glycosylated fibronectin in predicting adverse neonatal outcome in women with suspected pre‐eclampsia

Ultrasound Prediction of Abnormal Infant Development in Hypertensive Pregnant Women in the Second and Third Trimester

EP17.13: CVRI as a quick method to estimate peripheral vascular resistance at 13–16 weeks of gestation in patients at high risk of pre‐eclampsia

EP17.06: Inter‐manufacturer assessment of the diagnostic performance of angiogenic ratio versus glycosylated fibronectin in women with suspected pre‐eclampsia

EP17.66: Prenatal care strategy using clinical factors for pre‐eclampsia risk prediction and prophylaxis indication

EP17.15: Evaluation of clinical and biophysical markers as a screening test for late‐onset pre‐eclampsia between 35 and 38 weeks of gestation

Development and Validation of Multi-Stage Prediction Models for Pre-eclampsia: A Retrospective Cohort Study on Chinese Women

Doppler Studies of Maternal Uterine Artery and Fetal Circulation in Women with Early-Onset of Severe Preeclampsia

Fetal and Neonatal Middle Cerebral Artery Hemodynamic Changes and Significance under Ultrasound Detection in Hypertensive Disorder Complicating Pregnancy Patients with Different Severities

Bioinformatics identification and validation of maternal blood biomarkers and immune cell infiltration in preeclampsia: An observational study

OC17.06: *First trimester cardiac function in women with and without high risk of pre‐eclampsia

EP12.08: Risk of superimposed pre‐eclampsia and adverse outcomes in pregnant women with chronic hypertension

Pre-eclampsia and the foetus: a cardiovascular perspective

Development of non-invasive biomarkers for pre-eclampsia through data-driven cardiovascular network models